Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.36 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.34 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.34 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 6/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27007071 | 1.00 | TSHR (0.44) | TSHRCYP2D6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL1753673 | 0.98 | CYP2D6 (0.41) | TSHRCYP2D6CYP3A4ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL19717229 | 0.87 | CYP2D6 (0.49) | TSHRCYP2D6CYP3A4ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL9688286 | 0.87 | TSHR (0.59) | TSHRCYP2D6CYP3A4ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL21058494 | 0.87 | CYP2D6 (0.49) | TSHRCYP2D6CYP3A4ALDH1A1CYP1A2 | |
| Oxalic Acid SCHEMBL29701092 | 0.86 | USP2 (0.42) | TSHRCYP2D6CYP3A4ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL2761785 | 0.86 | CYP2D6 (0.44) | TSHRCYP2D6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL7711019 | 0.84 | CYP2D6 (0.50) | TSHRCYP2D6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL13879323 | 0.84 | TSHR (0.56) | TSHRCYP2D6CYP3A4ALDH1A1CYP1A2 | |
| SCHEMBL12457837 | 0.84 | TSHR (0.56) | TSHRCYP2D6CYP3A4ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12257254-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2025-03-25 | — | — | US | disclosed |
| US-20240174696-A1 | 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS | GENENTECH, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| CN-117980297-A | Substituted aminopyridine compounds as EGFR inhibitors | 柳韩洋行 | 2024-05-03 | — | — | CN | disclosed |
| EP-4347594-A1 | 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS | Genentech, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117425654-A | 2, 8-diazaspiro [4.5] decane compounds | 基因泰克公司 | 2024-01-19 | — | — | CN | disclosed |
| US-11779586-B2 | Compounds comprising tricyclic heterocyclic compounds | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2023-10-10 | — | — | US | disclosed |
| US-11708378-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2023-07-25 | — | — | US | disclosed |
| US-20230066999-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | KARUS THERAPEUTICS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| EP-3337460-B1 | COMPOSITIONS COMPRISING TRICYCLIC HETEROCYCLIC COMPOUNDS | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-15 | — | — | EP | disclosed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | disclosed |
| WO-2017029518-A1 | COMPOSITIONS COMPRISING TRICYCLIC HETEROCYCLIC COMPOUNDS | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017029514-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| EP-3105233-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | Karus Therapeutics Limited (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-20160347771-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2016-12-01 | — | — | US | disclosed |
| WO-2015121657-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2015-08-20 | — | — | WO | disclosed |
| US-20140141099-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-05-22 | — | — | US | disclosed |
| US-20110269732-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2148931-A2 | DRUG DISCOVERY METHODS FOR AURORA KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008131103-A2 | DRUG DISCOVERY METHODS FOR AURORA KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708378-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | PIK3CA, PIK3C2A, PIK3C2B | MAOB 3319/4885GABRD 4114/4885GABRA1 3716/4885 |
| US-20240174696-A1 | 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS | LATS1, LATS2, GLS2 | MAOB 4583/4885GABRD 69/4885GABRA1 352/4885 |
| US-20100137305-A1 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | MAOB 2712/4885GABRD 4843/4885GABRA1 4791/4885 |
| US-12257254-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | MAOB 3312/4885GABRD 4155/4885GABRA1 3783/4885 |
| US-20160347771-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3C2A, PIK3C2B | MAOB 3319/4885GABRD 4114/4885GABRA1 3716/4885 |
| US-20140141099-A1 | DRUG DISCOVERY METHODS | AURKB, AURKC, AURKA | MAOB 1367/4885GABRD 4786/4885GABRA1 4402/4885 |
| US-11779586-B2 | Compounds comprising tricyclic heterocyclic compounds | GRN, GLA, HTT | MAOB 703/4885GABRD 1317/4885GABRA1 1684/4885 |
| US-20110269732-A1 | DRUG DISCOVERY METHODS | AURKB, AURKC, AURKA | MAOB 1367/4885GABRD 4786/4885GABRA1 4402/4885 |
| US-20230066999-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | MCL1, MYC, XIAP | MAOB 3312/4885GABRD 4155/4885GABRA1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.